Literature DB >> 33398565

Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study.

A Balduzzi1,2, J van Hilst3, M Korrel3, S Lof3,4, B Al-Sarireh5, A Alseidi6, F Berrevoet7, B Björnsson8, P van den Boezem9, U Boggi10, O R Busch3, G Butturini11, R Casadei12, R van Dam13,14, S Dokmak15, B Edwin16, M A Sahakyan16,17, G Ercolani18,19, J M Fabre20, M Falconi21, A Forgione22, B Gayet23, D Gomez24, B Groot Koerkamp25, T Hackert26, T Keck27, I Khatkov28, C Krautz29, R Marudanayagam30, K Menon31, A Pietrabissa32, I Poves33, A Sa Cunha34, R Salvia35, S Sánchez-Cabús36, Z Soonawalla37, M Abu Hilal38,39,40, M G Besselink41.   

Abstract

BACKGROUND: A radical left pancreatectomy in patients with pancreatic ductal adenocarcinoma (PDAC) may require extended, multivisceral resections. The role of a laparoscopic approach in extended radical left pancreatectomy (ERLP) is unclear since comparative studies are lacking. The aim of this study was to compare outcomes after laparoscopic vs open ERLP in patients with PDAC.
METHODS: An international multicenter propensity-score matched study including patients who underwent either laparoscopic or open ERLP (L-ERLP; O-ERLP) for PDAC was performed (2007-2015). The ISGPS definition for extended resection was used. Primary outcomes were overall survival, margin negative rate (R0), and lymph node retrieval.
RESULTS: Between 2007 and 2015, 320 patients underwent ERLP in 34 centers from 12 countries (65 L-ERLP vs. 255 O-ERLP). After propensity-score matching, 44 L-ERLP could be matched to 44 O-ERLP. In the matched cohort, the conversion rate in L-ERLP group was 35%. The L-ERLP R0 resection rate (matched cohort) was comparable to O-ERLP (67% vs 48%; P = 0.063) but the lymph node yield was lower for L-ERLP than O-ERLP (median 11 vs 19, P = 0.023). L-ERLP was associated with less delayed gastric emptying (0% vs 16%, P = 0.006) and shorter hospital stay (median 9 vs 13 days, P = 0.005), as compared to O-ERLP. Outcomes were comparable for additional organ resections, vascular resections (besides splenic vessels), Clavien-Dindo grade ≥ III complications, or 90-day mortality (2% vs 2%, P = 0.973). The median overall survival was comparable between both groups (19 vs 20 months, P = 0.571). Conversion did not worsen outcomes in L-ERLP.
CONCLUSION: The laparoscopic approach may be used safely in selected patients requiring ERLP for PDAC, since morbidity, mortality, and overall survival seem comparable, as compared to O-ERLP. L-ERLP is associated with a high conversion rate and reduced lymph node yield but also with less delayed gastric emptying and a shorter hospital stay, as compared to O-ERLP.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  ERLP; Extended resection; Left pancreatectomy; PDAC

Mesh:

Year:  2021        PMID: 33398565     DOI: 10.1007/s00464-020-08206-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  19 in total

Review 1.  Isolation of right main and right sectional portal pedicles for liver resection without hepatotomy or inflow occlusion.

Authors:  Steven M Strasberg; David C Linehan; William G Hawkins
Journal:  J Am Coll Surg       Date:  2007-09-20       Impact factor: 6.113

2.  Novel approach for removal of a fistulating oesophageal stent: an ileostomy.

Authors:  Brian J Miller; Neil K Wylie
Journal:  ANZ J Surg       Date:  2013-07       Impact factor: 1.872

3.  Implementation of enhanced recovery programme for laparoscopic distal pancreatectomy: feasibility, safety and cost analysis.

Authors:  John Richardson; Francesco Di Fabio; Hannah Clarke; Mohammed Bajalan; Joe Davids; Mohammed Abu Hilal
Journal:  Pancreatology       Date:  2015-01-20       Impact factor: 3.996

4.  Reply to "Resection of the mesopancreas in pancreatic head adenocarcinoma: Is it outside of the International Study Group on Pancreatic Surgery definition and consensus statement for standard and extended pancreatectomy?".

Authors:  Werner Hartwig; Dirk J Gouma; Richard M Charnley; Markus W Büchler
Journal:  Surgery       Date:  2015-04-18       Impact factor: 3.982

5.  Risk factors for surgical complications in distal pancreatectomy.

Authors:  Hendrik Seeliger; Simone Christians; Martin K Angele; Axel Kleespies; Martin E Eichhorn; Ivan Ischenko; Stefan Boeck; Volker Heinemann; Karl-Walter Jauch; Christiane J Bruns
Journal:  Am J Surg       Date:  2010-04-09       Impact factor: 2.565

6.  Author response to: Comment on: The LAPOP trial of laparoscopic or open distal pancreatectomy.

Authors:  B Björnsson; A Lindhoff Larsson; C Hjalmarsson; T Gasslander; P Sandström
Journal:  Br J Surg       Date:  2020-07-11       Impact factor: 6.939

Review 7.  Advanced-stage pancreatic cancer: therapy options.

Authors:  Jens Werner; Stephanie E Combs; Christoph Springfeld; Werner Hartwig; Thilo Hackert; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2013-04-30       Impact factor: 66.675

8.  Multicentre observational cohort study of implementation and outcomes of laparoscopic distal pancreatectomy.

Authors:  S Lof; A L Moekotte; B Al-Sarireh; B Ammori; S Aroori; D Durkin; G K Fusai; J J French; D Gomez; G Marangoni; R Marudanayagam; Z Soonawalla; R Sutcliffe; S A White; M Abu Hilal
Journal:  Br J Surg       Date:  2019-08-27       Impact factor: 6.939

9.  Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection.

Authors:  Jennifer L Irani; Stanley W Ashley; David C Brooks; Robert T Osteen; Chandrajit P Raut; Sara Russell; Richard S Swanson; Edward E Whang; Michael J Zinner; Thomas E Clancy
Journal:  J Gastrointest Surg       Date:  2008-08-02       Impact factor: 3.452

10.  Is there still a role for total pancreatectomy?

Authors:  Michael W Müller; Helmut Friess; Jörg Kleeff; Rolf Dahmen; Markus Wagner; Ulf Hinz; Daniela Breisch-Girbig; Güralp O Ceyhan; Markus W Büchler
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.